What is methadone and how does it differ from Suboxone?
Methadone is a long-acting full mu-opioid agonist, while Suboxone (buprenorphine) is a partial agonist. Methadone fully activates opioid receptors at therapeutic doses, which makes it effective for patients with high opioid tolerance — including long-term heroin, fentanyl, and prescription opioid users — who may not stabilize on a partial agonist.
The clinical trade-off is regulatory. Methadone for opioid use disorder is dispensed only at federally certified Opioid Treatment Programs (OTPs) under 42 CFR Part 8. Patients typically dose daily on-site during induction and the early stabilization phase, with take-home privileges earned over time. Suboxone, by contrast, can be prescribed in any qualified physician office.
Both medications cut opioid overdose mortality by more than 50% (NIDA) and are first-line treatments under SAMHSA TIP 63.
How does Ascend coordinate with methadone OTPs?
Ascend refers clients to certified OTPs in Palm Beach County for methadone induction and dispensing, while providing the behavioral health treatment that methadone-alone does not address. The coordinated care model is built into the client's treatment plan from intake.
- OTP referral and intake support: Direct warm hand-off to a partner OTP, assistance with paperwork and transportation logistics.
- Schedule integration: PHP and IOP scheduling built around daily OTP dosing windows.
- Clinical communication: Release-of-information agreements that allow OTP physicians and Ascend clinicians to coordinate dose adjustments, drug screens, and progress notes.
- Behavioral programming: Individual therapy, group therapy, psychiatric care, and trauma treatment delivered at Ascend.
SAMHSA TIP 63 emphasizes that medication plus behavioral treatment outperforms either modality alone — and methadone OTPs typically deliver minimal behavioral programming on their own.
Questions About How does Ascend coordinate?
Call our 24/7 admissions line or verify your insurance online.
Why is methadone restricted to OTPs only?
Federal regulation under 42 CFR Part 8 restricts methadone for opioid use disorder to certified Opioid Treatment Programs. The restriction reflects methadone's pharmacology as a full opioid agonist with substantial overdose risk during induction, particularly for opioid-naive patients or those with respiratory or cardiac conditions.
OTPs are required to provide daily observed dosing during the early treatment phase, regular drug screening, medical and counseling services, and structured take-home dose privileges based on demonstrated stability. There are approximately 1,800 OTPs nationally (SAMHSA), with multiple programs in Palm Beach County.
The regulatory framework is the reason Ascend coordinates methadone treatment through partner OTPs rather than dispensing on site. Suboxone and Vivitrol are not subject to the same restrictions and are administered directly at Ascend.
“Methadone is one of the most studied treatments in medicine. For the right patient — high tolerance, long use history, partial agonist failures — it is often the strongest option we have. Coordinated with structured behavioral care, retention and outcomes climb sharply.”
What clinical care complements methadone treatment?
Methadone normalizes brain chemistry and removes daily withdrawal — but the cognitive, behavioral, and relational drivers of opioid use disorder require dedicated treatment. Ascend's methadone-coordinated programming addresses these layers.
- Individual therapy: CBT, motivational interviewing, EMDR and CPT for co-occurring trauma.
- Group therapy: Process groups, relapse prevention, psychoeducation, and family programming.
- Psychiatric care: Evaluation and medication management for co-occurring depression, anxiety, bipolar disorder, and PTSD.
- Case management: Housing, employment, legal, and OTP coordination support.
NIDA research shows that retention in methadone treatment at 12 months reaches 60–70% when paired with behavioral programming — significantly higher than methadone-alone models.